Unknown

Dataset Information

0

Discovery of prenylated flavonoids with dual activity against influenza virus and Streptococcus pneumoniae.


ABSTRACT: Influenza virus neuraminidase (NA) is the primary target for influenza therapeutics. Severe complications are often related to secondary pneumonia caused by Streptococcus pneumoniae (pneumococci), which also express NAs. Recently, a NA-mediated lethal synergism between influenza A viruses and pneumococci was described. Therefore, dual inhibitors of both viral and bacterial NAs are expected to be advantageous for the treatment of influenza. We investigated the traditional Chinese herbal drug s?ng bái pí (mulberry root bark) as source for anti-infectives. Two prenylated flavonoid derivatives, sanggenon G (4) and sanggenol A (5) inhibited influenza A viral and pneumococcal NAs and, in contrast to the approved NA inhibitor oseltamivir, also planktonic growth and biofilm formation of pneumococci. Evaluation of 27 congeners of 5 revealed a correlation between the degree of prenylation and bioactivity. Abyssinone-V 4'-methyl ether (27) inhibited pneumococcal NA with IC50?=?2.18??M, pneumococcal growth with MIC?=?5.63??M, and biofilm formation with MBIC?=?4.21??M, without harming lung epithelial cells. Compounds 5 and 27 also disrupt the synergism between influenza A virus and pneumococcal NA in vitro, hence functioning as dual-acting anti-infectives. The results warrant further studies on whether the observed disruption of this synergism is transferable to in vivo systems.

SUBMITTER: Grienke U 

PROVIDER: S-EPMC4891693 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Discovery of prenylated flavonoids with dual activity against influenza virus and Streptococcus pneumoniae.

Grienke Ulrike U   Richter Martina M   Walther Elisabeth E   Hoffmann Anja A   Kirchmair Johannes J   Makarov Vadim V   Nietzsche Sandor S   Schmidtke Michaela M   Rollinger Judith M JM  

Scientific reports 20160603


Influenza virus neuraminidase (NA) is the primary target for influenza therapeutics. Severe complications are often related to secondary pneumonia caused by Streptococcus pneumoniae (pneumococci), which also express NAs. Recently, a NA-mediated lethal synergism between influenza A viruses and pneumococci was described. Therefore, dual inhibitors of both viral and bacterial NAs are expected to be advantageous for the treatment of influenza. We investigated the traditional Chinese herbal drug sāng  ...[more]

Similar Datasets

| S-EPMC6278664 | biostudies-literature
| S-EPMC3605146 | biostudies-literature
2022-12-09 | PXD016214 | Pride
| S-EPMC8395381 | biostudies-literature
2022-12-09 | PXD016122 | Pride
| S-EPMC7583851 | biostudies-literature
| S-EPMC4402582 | biostudies-literature